AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7598243 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg
Number of subjects: 360
Study 7598243 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study 1964885 — intervention group
Group type: EXPERIMENTAL
Intervention: NET-OEN (50 mg) + E2 valerate (5 mg) given every month
Number of subjects: 849
Study 1964885 — intervention group
Group type: COMPARATOR
Intervention: NET-OEN (200 mg) given every 2 months
Number of subjects: 849
Study 155389 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-nicotinamide
Number of subjects: 25
Study 155389 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 25
Study 155389 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-nicotinamide-imipramine combination
Number of subjects: 25
Study 155389 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study 31485282 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-CPAP
Number of subjects: 269
Study 31485282 — intervention group
Group type: COMPARATOR
Intervention: Fixed-CPAP
Number of subjects: 269
Study 31485282 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP level
Number of subjects: 269
Study 31485282 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal masks
Number of subjects: 269
Study 31485282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco consumption
Number of subjects: 269
Study 28417153 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy
Number of subjects: 74
Study 28417153 — intervention group
Group type: COMPARATOR
Intervention: Open abdominal sacrocolpopexy
Number of subjects: 74
Study 26473975 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular intake of carotenoids from supplements and medications in amounts > 6.8 mg/d (upper tertile)
Number of subjects: 4447
Study 26473975 — intervention group
Group type: COMPARATOR
Intervention: No intake of carotenoids
Number of subjects: 4447
Study 23647889 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention for 1 hour daily for 3 months along with oral hypoglycemic drugs
Number of subjects: 100
Study 23647889 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemic drugs
Number of subjects: 100
Study 21138361 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% grape juice made from Concord grapes
Number of subjects: 85
Study 21138361 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 85
Study 18534438 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily
Number of subjects: 1896
Study 18534438 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once daily
Number of subjects: 1896
Study 18534438 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 30 mg SC BID
Number of subjects: 1896
Study 16887327 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone containing oral contraceptive pill (Yasmin)
Number of subjects: 0
Study 16887327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15083986 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (beclomethasone metered-dose inhaler, tapering 4-week course)
Number of subjects: 11
Study 15083986 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroids (7-day course)
Number of subjects: 11
Study 11454107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted voiding (PV) during nighttime
Number of subjects: 61
Study 11454107 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime prompted voiding (PV)
Number of subjects: 61
Study 9496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg intravenously
Number of subjects: 124
Study 9496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 124
Study 9496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg intravenously
Number of subjects: 124
Study 9496526 — intervention group
Group type: COMPARATOR
Intervention: Control group (45 healthy men)
Number of subjects: 124
Study 8049632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking at the time of diagnosis
Number of subjects: 0
Study 8049632 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 0
Study 8049632 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of cigarettes smoked per day and cumulative exposure (pack-years of use)
Number of subjects: 0
Study 8049632 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking at the time of diagnosis, high pack-years of use, and smoking at the time of menarche
Number of subjects: 0
Study 2647270 — intervention group
Group type: EXPERIMENTAL
Intervention: desipramine (150 mg/day)
Number of subjects: 24
Study 2647270 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 31320350 — intervention group
Group type: EXPERIMENTAL
Intervention: Smell and taste of milk with each tube feed
Number of subjects: 0
Study 31320350 — intervention group
Group type: COMPARATOR
Intervention: Tube feeding without the provision of smell and taste
Number of subjects: 0
Study 30159779 — intervention group
Group type: EXPERIMENTAL
Intervention: DC vaccine (DCV)
Number of subjects: 43
Study 30159779 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 43
Study 27015544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 2.5 ppm DEX
Number of subjects: 18
Study 27015544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 5.0 ppm DEX
Number of subjects: 18
Study 27015544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 7.5 ppm DEX
Number of subjects: 18
Study 27015544 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine with 1:80,000 AD
Number of subjects: 18
Study 25408735 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (2×500 mg) + Amoxicillin (2×1 gr) + Omeprazole (2×20 mg) for 14 days
Number of subjects: 78
Study 25408735 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (1×250 mg) + Amoxicillin (2×1 gr) + Omeprazole (2×20 mg) for 10 days
Number of subjects: 78
Study 21978087 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy in addition to routine nursing care
Number of subjects: 120
Study 21978087 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 120
Study 20808794 — intervention group
Group type: COMPARATOR
Intervention: Industry funded RCTs
Number of subjects: 188
Study 20808794 — intervention group
Group type: COMPARATOR
Intervention: Non-profit and mixed funding RCTs
Number of subjects: 188
Study 20808794 — intervention group
Group type: COMPARATOR
Intervention: Any actual costs included
Number of subjects: 188
Study 20808794 — intervention group
Group type: COMPARATOR
Intervention: Any mention of costs
Number of subjects: 188
Study 20808794 — intervention group
Group type: COMPARATOR
Intervention: Any actual costs or mention of costs
Number of subjects: 188
Study 17698978 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized herbal treatment from qualified herbal practitioners (n = 15), six consultations over 5 months
Number of subjects: 45
Study 17698978 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30) offered treatment after waiting 4 months
Number of subjects: 45
Study 17698978 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized herbal treatment
Number of subjects: 45
Study 15618072 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 30
Study 15618072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12375708 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group
Number of subjects: 72
Study 12375708 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 12375708 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (compliant patients)
Number of subjects: 72
Study 9932956 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interferon beta-1b (8.0 mIU)
Number of subjects: 0
Study 9932956 — intervention group
Group type: COMPARATOR
Intervention: Low dose interferon beta-1b (1.6 mIU)
Number of subjects: 0
Study 9932956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7586436 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative steroid (Solumedrol 250 mg IV, n = 16)
Number of subjects: 25
Study 7586436 — intervention group
Group type: COMPARATOR
Intervention: No steroid (n = 9, control group)
Number of subjects: 25
Study 2310577 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia with bupivacaine (three different dosage regimens)
Number of subjects: 0
Study 400045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 29
Study 400045 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 29
Study 31540980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifastuzumab vedotin (LIFA) at 2.4 mg/kg once every 3 weeks
Number of subjects: 87
Study 31540980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifastuzumab vedotin (LIFA) at doses ≥1.8 mg/kg
Number of subjects: 87
Study 30722014 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g milk protein concentrate
Number of subjects: 48
Study 30722014 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g milk protein concentrate
Number of subjects: 48
Study 30722014 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 g milk protein concentrate
Number of subjects: 48
Study 29518135 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF test (post-Xpert group)
Number of subjects: 620
Study 29518135 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostic tests (pre-Xpert group)
Number of subjects: 620
Study 26454537 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased end-diastolic wall stress
Number of subjects: 1050
Study 26454537 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased end-systolic wall stress
Number of subjects: 1050
Study 26454537 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal end-systolic wall stress <18 kPa
Number of subjects: 1050
Study 26454537 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced PFR
Number of subjects: 1050
Study 24968645 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-Force Bite Corrector (TFBC)
Number of subjects: 10
Study 24968645 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator
Number of subjects: 10
Study 24968645 — intervention group
Group type: COMPARATOR
Intervention: Control Group (untreated)
Number of subjects: 10
Study 22326504 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg atrasentan
Number of subjects: 0
Study 22326504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75 mg atrasentan
Number of subjects: 0
Study 22326504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22326504 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg atrasentan (Hispanic subjects)
Number of subjects: 0
Study 22326504 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg atrasentan (non-Hispanic subjects)
Number of subjects: 0
Study 22326504 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum doses of RAS inhibitors
Number of subjects: 0
Study 20191466 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication about medication costs during visits
Number of subjects: 193
Study 20191466 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics (white race, income $20,000-$59,999)
Number of subjects: 193
Study 20191466 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician characteristics (white race)
Number of subjects: 193
Study 20191466 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication changes
Number of subjects: 193
Study 17412530 — intervention group
Group type: EXPERIMENTAL
Intervention: 1MIRP (4 weekly individual sessions of motivational interviewing and relapse prevention over 1 month)
Number of subjects: 160
Study 17412530 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MIRP (4 weekly individual sessions of motivational interviewing and relapse prevention over 3 months)
Number of subjects: 160
Study 17412530 — intervention group
Group type: COMPARATOR
Intervention: DTC (Delayed Treatment Control)
Number of subjects: 160
Study 17722316 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg intravaginal misoprostol
Number of subjects: 50
Study 17722316 — intervention group
Group type: COMPARATOR
Intervention: 400 microg intravaginal misoprostol
Number of subjects: 50
Study 17722316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 12154111 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (3 ng/kg per minute for 45 minutes) and captopril during low salt balance
Number of subjects: 41
Study 12154111 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt intake (200 mmol/d)
Number of subjects: 41
Study 12154111 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt intake (10 mmol/d)
Number of subjects: 41
Study 12154111 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin activity
Number of subjects: 41
Study 10834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) from related donors
Number of subjects: 118
Study 10834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) from unrelated donors
Number of subjects: 118
Study 10834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (SCT)
Number of subjects: 118
Study 10834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) beyond the first CR
Number of subjects: 118
Study 10834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) in the first CR
Number of subjects: 118
Study 10834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated stem-cell grafting
Number of subjects: 118
Study 10834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem-cell grafting
Number of subjects: 118
Study 10834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative therapy followed by allogeneic stem-cell infusion
Number of subjects: 118
Study 10834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant-related mortality
Number of subjects: 118
Study 8823101 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Duraflo II), n = 107
Number of subjects: 217
Study 8823101 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncoated circuit), n = 110
Number of subjects: 217
Study 1454638 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal radiographs interpreted by pediatric emergency physicians
Number of subjects: 126
Study 2994148 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg every morning for 14 days
Number of subjects: 12
Study 2994148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30832742 — intervention group
Group type: EXPERIMENTAL
Intervention: IgGAM infusions for 5 days
Number of subjects: 200
Study 30832742 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment (SoC)
Number of subjects: 200
Study 30212438 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation intervention (QUIT) - 9-week program with 1 psychoeducation session and 9 weekly 1-hour sessions of cognitive behavioral therapy plus nicotine replacement therapy.
Number of subjects: 72
Study 30212438 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard smoking intervention (ETAU) - 9-week program with 1 psychoeducation session and 4 brief weekly check-in sessions plus nicotine replacement therapy.
Number of subjects: 72
Study 27097348 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV + DTPa‐HBV‐IPV/Hib
Number of subjects: 774
Study 27097348 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV + DTPa‐IPV‐Hib
Number of subjects: 774
Study 27097348 — intervention group
Group type: COMPARATOR
Intervention: 7‐valent pneumococcal conjugate vaccine (7vCRM) + DTPa‐IPV‐Hib
Number of subjects: 774
Study 25040965 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call
Number of subjects: 1000
Study 25040965 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 1000
Study 25040965 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered letter
Number of subjects: 1000
Study 25040965 — intervention group
Group type: COMPARATOR
Intervention: Postal letter
Number of subjects: 1000
Study 22417026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol (1 mg/kg; 0.5 mg/kg propofol plus 0.5 mg/kg ketamine)
Number of subjects: 24
Study 22417026 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1 mg/kg)
Number of subjects: 24
Study 22417026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 24
Study 20375405 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg) and Vitamin E (400 IU) supplementation
Number of subjects: 10154
Study 20375405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10154
Study 18422960 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha2a plus ribavirin
Number of subjects: 183
Study 18422960 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha2b plus ribavirin
Number of subjects: 183
Study 16002175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3700
Study 16002175 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3700
Study 16002175 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 3700
Study 12640474 — intervention group
Group type: COMPARATOR
Intervention: Albendazole + placebo
Number of subjects: 0
Study 12640474 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin + placebo
Number of subjects: 0
Study 12640474 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine + placebo
Number of subjects: 0
Study 12640474 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole + ivermectin
Number of subjects: 0
Study 12640474 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole + diethylcarbamazine
Number of subjects: 0
Study 10843434 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroid (budesonide) for 6 weeks
Number of subjects: 80
Study 10843434 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta2‐agonist (terbutaline) for 6 weeks followed by inhaled steroid for 2 weeks
Number of subjects: 80
Study 10843434 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 80
Study 8704117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol
Number of subjects: 8
Study 8704117 — intervention group
Group type: COMPARATOR
Intervention: Acute metabolic acidosis
Number of subjects: 8
Study 1636162 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐purity pasteurized FVIII concentrate
Number of subjects: 8
Study 1636162 — intervention group
Group type: COMPARATOR
Intervention: Intermediate purity pasteurized FVIII concentrate
Number of subjects: 8
Study 1636162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 8
Study 29999185 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based ACT (ACTivate Your Life after Stroke)
Number of subjects: 53
Study 29999185 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 53
Study 28953631 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVBRA with 20 mL 0.25% bupivacaine + 1 μg/kg dexmedetomidine
Number of subjects: 72
Study 28953631 — intervention group
Group type: COMPARATOR
Intervention: TPVBRA with 20 mL 0.25% bupivacaine
Number of subjects: 72
Study 25955980 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% Topical Diclofenac
Number of subjects: 28
Study 25955980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23369038 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1,000 mg sustained release (SR) tablets
Number of subjects: 500
Study 23369038 — intervention group
Group type: COMPARATOR
Intervention: Conventional paracetamol 500 mg tablets
Number of subjects: 500
Study 21208923 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterotypic vaccine
Number of subjects: 36
Study 21208923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19353315 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological dressing (Xenoderm)
Number of subjects: 118
Study 19353315 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 118
Study 17535594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 19
Study 17535594 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 19
Study 15161118 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-6 mg/day
Number of subjects: 32
Study 15161118 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus nimodipine
Number of subjects: 32
Study 11465702 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Number of subjects: 53
Study 11465702 — intervention group
Group type: COMPARATOR
Intervention: Disease-Modifying Antirheumatic Drugs (DMARDs)
Number of subjects: 53
Study 9570492 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants treatment for 5 weeks
Number of subjects: 0
Study 9570492 — intervention group
Group type: COMPARATOR
Intervention: Non-responders to antidepressants
Number of subjects: 0
Study 8068589 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled infusion of midazolam
Number of subjects: 0
Study 8068589 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of midazolam
Number of subjects: 0
Study 3059852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg.kg‐1 midazolam intravenously 3 to 5 min prior to induction with fentanyl (5 micrograms.kg‐1.min‐1)
Number of subjects: 16
Study 3059852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31017079 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli samples
Number of subjects: 314
Study 31017079 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli resistance profile
Number of subjects: 314
Study 31017079 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli isolates
Number of subjects: 314